An Update Review of Biosimilars of Adalimumab in Psoriasis - Bioequivalence and Interchangeability
- PMID: 34267501
- PMCID: PMC8275172
- DOI: 10.2147/DDDT.S317382
An Update Review of Biosimilars of Adalimumab in Psoriasis - Bioequivalence and Interchangeability
Abstract
Biologic drugs have revolutionized the treatment of psoriasis and other rheumatological diseases. In recent years, many biosimilar agents that are highly similar in structure and function to their originator products have been developed, including the tumor necrosis factor-alpha antagonist adalimumab. The considerably lower cost of these products has greatly cut the economic burden of the patients and increased the accessibility of biologic therapies worldwide. The US Food and Drug Administration and/or the European Medicines Agency have approved eight biosimilars of adalimumab (ABP 501/BI 695501/SB5/GP2017/FKB327/MSB11022/PF-06410293/CT-P17) for the treatment of psoriasis, and others are under review. Given that these agents showed pharmacokinetic, efficacy, safety, and immunogenicity profiles comparable to those of the originator, adalimumab biosimilars were licensed for all indications approved for reference adalimumab based on extrapolation; however, some of the equivalence studies were only conducted in one or two disease populations. This review discusses the bioequivalence of adalimumab biosimilars as demonstrated by various clinical trials, the extrapolation of indications, guidance and policies of the EU and US on interchangeability (nonmedical switching/automatic substitution) between biosimilars and originators, and the real-life practices of switching from reference adalimumab to the respective biosimilars. Further data from real-world studies and post-marketing analyses are needed better to address the efficacy and safety of the transition strategy.
Keywords: adalimumab; biosimilar; extrapolation of indications; guidance of interchangeability; psoriasis.
© 2021 Zhou et al.
Conflict of interest statement
The authors report no conflicts of interest in this work.
Similar articles
-
Safety and Effectiveness of Anti-Tumor Necrosis Factor-Alpha Biosimilar Agents in the Treatment of Psoriasis.Am J Clin Dermatol. 2020 Aug;21(4):483-491. doi: 10.1007/s40257-020-00507-1. Am J Clin Dermatol. 2020. PMID: 32048187 Review.
-
Pharmacokinetic equivalence of CT-P17 to high-concentration (100 mg/ml) reference adalimumab: A randomized phase I study in healthy subjects.Clin Transl Sci. 2021 Jul;14(4):1280-1291. doi: 10.1111/cts.12967. Epub 2021 Mar 2. Clin Transl Sci. 2021. PMID: 33503313 Free PMC article. Clinical Trial.
-
Efficacy and Safety Outcomes for Originator TNF Inhibitors and Biosimilars in Rheumatoid Arthritis and Psoriasis Trials: A Systematic Literature Review.BioDrugs. 2018 Jun;32(3):193-199. doi: 10.1007/s40259-018-0283-4. BioDrugs. 2018. PMID: 29790131 Review.
-
A Randomized, Double-Blind, Parallel-Group, Phase 1 Clinical Trial Comparing the Pharmacokinetic, Safety, and Immunogenicity of the Biosimilar HS016 and the Originator Adalimumab in Chinese Healthy Male Subjects.Clin Pharmacol Drug Dev. 2021 Mar;10(3):317-325. doi: 10.1002/cpdd.816. Epub 2020 May 28. Clin Pharmacol Drug Dev. 2021. PMID: 32463599 Free PMC article. Clinical Trial.
-
Biosimilars for the treatment of psoriasis.Expert Opin Biol Ther. 2019 Oct;19(10):993-1000. doi: 10.1080/14712598.2019.1636963. Epub 2019 Jul 1. Expert Opin Biol Ther. 2019. PMID: 31237786 Review.
Cited by
-
Real-Life Effectiveness of Adalimumab Biosimilars in Patients with Chronic Plaque Psoriasis.Dermatol Ther (Heidelb). 2022 Jun;12(6):1303-1311. doi: 10.1007/s13555-022-00732-y. Epub 2022 Apr 27. Dermatol Ther (Heidelb). 2022. PMID: 35476248 Free PMC article.
-
A Phase I Clinical Trial to Evaluate the Bioequivalence of an Adalimumab Biosimilar Adalimumab-WIBP and Humira®.Clin Drug Investig. 2024 Dec;44(12):951-960. doi: 10.1007/s40261-024-01409-4. Epub 2024 Nov 15. Clin Drug Investig. 2024. PMID: 39546188 Clinical Trial.
-
Secukinumab Loss of Efficacy Is Perfectly Counteracted by the Introduction of Combination Therapy (Rescue Therapy): Data from a Multicenter Real-Life Study in a Cohort of Italian Psoriatic Patients That Avoided Secukinumab Switching.Pharmaceuticals (Basel). 2022 Jan 14;15(1):95. doi: 10.3390/ph15010095. Pharmaceuticals (Basel). 2022. PMID: 35056153 Free PMC article.
References
-
- The European Medicines Agency, The European Commission. Biosimilars in the EU - Information guide for healthcare professionals. Prepared jointly by the European Medicines Agency and the European Commission. ©European Med Agency; 2019. Available from: https://www.ema.europa.eu/en/documents/leaflet/biosimilars-eu-informatio.... Accessed July 26, 2020.
-
- U.S. Food & Drug Administration. Biosimilar and Interchangeable Products. Available from: https://www.fda.gov/drugs/biosimilars/biosimilar-and-interchangeable-pro.... Accessed August31, 2020.
-
- Ruff L, Rezk M, Uhlig T, Gommers J. Budget impact analysis of an etanercept biosimilar for the treatment of rheumatoid arthritis In Europe. Value Heal. 2015;18(7):A639. doi:10.1016/j.jval.2015.09.2276 - DOI
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical